Evaluation of Cardioprotective Potential of Drakshasava in Induced Diabetic Condition

 

Preeti Tiwari1*, Rakesh K. Patel2 and T.S. Eashwari3

1Head of Department of Pharmacognosy and Phytochemistry, IIMT College of Medical Sciences, Meerut, (U.P.) India

2Head of Department of Pharmacognosy, Shri S. K. Patel College of Pharmaceutical Education and Research, Kherva-382711, Gujarat, India

3Director (Pharmacy), IIMT College of Medical Sciences, Meerut, (U.P.) India

 

 

ABSTRACT:

The objective of the present study was to evaluate the effect of Drakshasava-T and Drakshasava-M prepared by traditional and modern methods respectively and marketed Drakshasava on fasting blood glucose and serum lipid profile in alloxan induced diabetic rats. Oral administration of Drakshasava-T, Drakshasava-M and marketed Drakshasava  (2 ml/kg p.o.) for 21 days caused a significant decrease in fasting blood glucose (FBG) and showed significant rise in blood glutathione level (GSH) in diabetic rats. Glibenclamide was used as a standard antidiabetic drug (10 mg/kg, p.o). These preparations also caused significant reduction in serum cholesterol, LDL and triglycerides and showed significant rise in serum HDL level in diabetic albino rats. Thus all these preparations were able to maintain the tested parameters near to the normal level significantly.

 

KEYWORDS: Cardiovascular risk, Blood glucose, anti-diabetic potential, glutathione, lipid profile, Drakshasava, alloxan.

 

 

1. INTRODUCTION:

Diabetics have accelerated levels of oxidative stress and this contributes massively to most cardiovascular, neurological, retinal and renal diabetic complications1. Diabetes mellitus is a heterogeneous metabolic disorder as old as mankind and its incidence is considered to be high all over the world2. It is characterized by hyperglycemia. Hyperglycemia significantly diminishes glutathione levels lowering defences against oxidative stress3.

 

A multitude of herbs, spices and other plant material has been described for the treatment of diabetes throughout the world4. Furthermore, after the recommendations made by WHO (World Health Organization) on diabetes mellitus, investigations on hypoglycaemic agents from medicinal plants have become more important. The levels of serum lipids are usually elevated in diabetes mellitus and such an elevation represents the risk factor for coronary heart disease. Moreover, diabetic patients experience a two to three fold increase in cardiovascular morbidity and mortality in comparison to non diabetics5.  

 

Drakshasava is a polyherbal hydroalcoholic preparation and is used to improve digestion, as blood purifier, in the treatment of anaemia and advised as a choice of remedy in respiratory problems. The chief ingredient of Drakshasava is draksha, dried fruits of Vitis vinifera6.

 

 

 


The composition and properties of fruits of Vitis vinifera  have been extensively investigated and it was reported that they contain large amount of phenolic compounds as catechins, epicatechin, quercetin and gallic acid, dimeric, trimeric and tetrameric procyanidins7-8. These compounds have many favourable effects on human health such as lowering of human low density lipoproteins, reduction of heart disease and cancer because of their antioxidant property9-16.

 

Therefore we undertook the present investigation to evaluate the antidiabetic effect of Drakshasava-T and Drakshasava-M prepared by traditional and modern methods respectively and also marketed Drakshasava in alloxan induced hyperglycemic rats. Effect of these preparations was also evaluated on the serum lipid profile of alloxan induced diabetic rats.

 

2. MATERIALS AND METHOD:

2.1 Preparation of Drakshasava-T

This was prepared by the method as given in Ayurvedic Formulary of India, Part-II6. The ingredients were procured from local market, Jamnagar. Identification of individual plant material was done as per Ayurvedic Pharmacopoeia of India. Authentication of all these ingredients was done by Dr.G. D. Bagchi, Scientist, Department of Taxonomy and Pharmacognosy, Central Institute of Medicinal and Aromatic Plants, Lucknow. Prepared herbarium has been deposited in CIMAP for future reference.

 

According to this method, dried fruits of Vitis vinifera were crushed and then placed in polished vessel of brass along with prescribed quantity of water (16.384 L), and allowed to steep overnight. After overnight steeping, this material was warmed at medium flame until the water for decoction reduced to one fourth of the prescribed quantity (4.096 L), then the heating was stopped and it was filtered through unstarched muslin cloth in cleaned and fumigated vessel and after that jaggery and honey were added and mixed properly. Then dhataki flowers (Woodfordia floribunda) and prescribed quantity of coarsely powdered prakshepa dravyas as Myristica fragrans (flowers), Eugenia caryophyllus (flower bud), Cubeba officinalis (fruits), Santalum album (heart wood), Piper nigrum (fruits), Cinnamomum zeylanicum (stem bark), Eletteria cardamomum (seeds) and Cinnamomum tamala (leaves) were added and this sweet filtered fluid was placed for fermentation in incubator for fifteen days at 33ºC± 1ºC.  After fifteen days, completion of fermentation was confirmed by standard tests17. The fermented preparation was filtered with unstarched muslin cloth and kept in cleaned covered vessel for further next seven days. Then, it was poured in clean amber colored glass bottles previously rinsed with ethyl alcohol, packed and labelled properly.

 

 

 

2.2 Preparation of Drakshasava-M:

Method of preparation was same as followed with Drakshasava-T, only dhataki flowers were replaced with yeast for inducing fermentation18.

 

2.3 Drugs and Chemicals:

Alloxan monohydrate was purchased from Loba Chemie, Mumbai. Standard antidiabetic drug glibenclamide was obtained from Ranbaxy Research Laboratories, Gurgaon, India.

 

2.4 Animals:

Adult Wistar albino rats, weighing between 200-220g of either sex were acclimatized to normal environmental conditions in the animal house for one week. The animals were housed in standard polypropylene cages and maintained under controlled room temperature (22 oC±2oC) and humidity (55±5%) with 12:12 hour light and dark cycle. All the animals were given a standard chow diet (Hindustan Lever Limited), and water ad libitum. The guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) of the Government of India were followed and prior permission was granted from the Institutional Animal Ethics Committee of Shri Sarvajanik Pharmacy College, Mehsana (CPCSEA No. 07/09).

 

2.5 Induction of Diabetes:

The animals were fasted for 18 h and made diabetic by injecting Alloxan monohydrate (150mg/kg, i.p.) dissolved in sterile normal saline. In order to stave off the hypoglycaemia during the first day, 5% w/v glucose solution was given orally to diabetic rats after four to six hours of alloxan administration. The diabetic state was confirmed when the blood sugar level was greater than 180 mg/dl19        .

 

2.6 Treatment Protocol:

All the animals were randomly divided into the six groups with six animals in each group. All the three types of Drakshasava as Drakshasava-T, Drakshasava-M and marketed Drakshasava were given at a dose of 2 ml/kg body weight, orally daily for a period of 21 days to different groups of diabetic animals.

Group I   : Normal animals received normal saline as vehicle (2 ml/kg, p.o.)

Group II  : Diabetic animals received normal saline as vehicle (2 ml/kg, p.o.)

Group III  : Diabetic animals received glibenclamide (10 mg/kg, p.o.)20

Group IV  : Diabetic animals received Drakshasava-T (2 ml/kg, p.o.)

Group V  : Diabetic animals received Drakshasava-M (2 ml/kg, p.o.)

Group VI    : Diabetic animals received marketed Drakshasava (2 ml/kg, p.o.)

Albino rats were made diabetic by a single intra-peritonial injection of alloxan monohydrate (Loba Chemie, Mumbai). Alloxan was first weighed individually for each animal according to the weight and then solubilized with 0.2ml saline just prior to injection. Two days after Alloxan monohydrate injection rats with blood glucose level of greater than 180mg/dl were selected for the present study. Treatment with Drakshasava-T, Drakshasava-M and marketed Drakshasava was started 48h after alloxan injection. Blood samples were drawn at weekly interval until the end of study i.e three weeks. Fasting blood glucose (FBG), blood glutathione (GSH) estimation and body weight measurement were done on day 1st, 7th, 14th and 21st of the study. On 21st day blood was collected by retro orbital plexus under mild ether anaesthesia and fasting blood glucose was estimated21. Serum was separated and analyzed for serum cholesterol22, serum triglycerides23, serum HDL24, serum LDL24, serum creatinine25, serum urea26, serum alkaline phosphatase27, blood glutathione28   by using Span and Erba diagnostic kits.

 

2.7 Statistical Analysis:

The results are expressed as mean ± SEM. Statistical analysis of data among the various groups was performed by using one way analysis of variance (ANOVA) followed by the Tukey’s test using Graph Pad Prism software of statistics. Significance value (P<0.05) was considered statistically significant as compared to control group.

 

3. RESULTS:

Effect      of Different Types of Drakshasava on FBG and GSH of Diabetic rats

All types of Drakshasava as Drakshasava–T, Drakshasava-M and marketed Drakshasava produced significant (P<0.001) reduction in FBG level in alloxan induced diabetic rats as compared to diabetic control group as shown in Figure 1(A). Glibenclamide showed highest significant reduction in FBG level (60%) as compared to diabetic control group. In our study, in alloxan treated diabetic rats the blood glutathione level (GSH) was found decreased significantly (P<0.001) as compared to normal control group as shown in Figure 1(B). Drakshasava-T, Drakshasava-M, marketed  Drakshasava (2 ml/kg p.o.) and glibenclamide (10 mg/kg p.o) showed significant increase in GSH level as compared to diabetic control group on both 14th and 21st day of treatment as shown in Figure 1(B).

 

Effect      of different types of Drakshasava on body weight of diabetic rats:

All types of Drakshasava preparations as Drakshasava-T, Drakshasava-M, marketed Drakshasava and glibenclamide exhibited significant antihyperglycemic activity in alloxan induced diabetic rats without causing significant change in body weight as shown in Figure 2.

 

Effect      of different types of Drakshasava on serum lipid profile of diabetic rats:

Drakshasava-T and Drakshasava-M at the dose of 2ml/kg body weight orally significantly reduced total serum cholesterol, serum LDL and triglycerides as compared to diabetic control while significant increase has been observed in the level of serum HDL in Drakshasava-T and Drakshasava-M treated groups as shown in Figure 3(A). Drakshasava-T and Drakshasava-M also significantly reduced serum creatinine as shown in Figure 3 (B). All the test preparations of Drakshasava also showed significant decrease in the level of serum alkaline phosphtase in alloxan induced diabetic rats as compared to diabetic control group as shown in Figure 3(C). Marketed Drakshasava produced similar effects on the serum lipid profile of diabetic rats as that of Drakshasava- T and Drakshasava-M whereas glibenclamide produced highest reduction in the levels of serum cholesterol, triglyceride and LDL as well as showed significant improvement in the level of HDL-cholesterol as compared to diabetic control.

 


 

Fig. 1(A) Effect of Drakshasava-T, M and marketed Drakshasava on fasting blood sugar (FBS) level in alloxan induced diabetic albino rats

All values are expressed as mean ± SEM (n = 6)

a P<0.001  significant as compared to normal group

b P<0.001  significant as compared to diabetic control group

 

           

     

 

 

Fig. 1(B) Effect of Drakshasava-T, M and marketed Drakshasava on blood glutathione (GSH) level in alloxan induced diabetic albino rats

All values are expressed as mean ± SEM (n = 6)

a  P<0.001  significant as compared to normal group

b  P<0.001  significant as compared to diabetic control group

 

 

Fig. 2 Effect of Drakshasava-T, M and marketed Drakshasava on the body weight of alloxan induced diabetic albino rats

All values are expressed as mean ± SEM (n = 6)

a P<0.001  significant as compared to normal group

b P<0.001  significant as compared to diabetic control group

 

Fig. 3(A) Effect of Drakshasava-T, M and marketed Drakshasava on serum lipid profile in alloxan induced diabetic albino rats

All values are expressed as mean ± SEM (n = 6)

a P<0.001  significant as compared to normal group, b P<0.001  significant as compared to diabetic control

 

Fig. 3(B) Effect of Drakshasava-T, M and marketed Drakshasava on serum creatinine in alloxan induced diabetic albino rats

All values are expressed as mean ± SEM (n = 6)

a P<0.001  significant as compared to normal group

b P<0.001  significant as compared to diabetic control group

 

 

Fig. 3(C) Effect of Drakshasava-T, M and marketed Drakshasava on serum alkaline phosphtase (ALP) in alloxan induced diabetic albino rats

All values are expressed as mean ± SEM (n = 6)

a P<0.001  significant as compared to normal group

b P<0.001  significant as compared to diabetic control group

 


 

4. DISCUSSION:

Administration of alloxan caused rapid destruction of pancreatic ß cells in rats, which led to impaired glucose stimulated insulin release and insulin resistance, both of which are marked feature of type II diabetes29. This is because administration of alloxan (150mg/kg i.p.) led to more than 1.5 fold elevation of fasting blood glucose level, which was maintained over a period of three weeks. Three week of daily treatment of Drakshasava-T, Drakshasava-M and marketed Drakshasava (2ml/kg p.o.) caused significant fall in blood glucose level.

 

GSH, being the most important bio-molecule against chemically induced toxicity can participate in the elimination of reactive intermediates by reduction of hydro-per-oxidase in the presence of glutathione per-oxidase. The most important mechanism implicated in the diabetogenic action of alloxan is by increased generation of oxygen free radicals which cause a decrease in plasma GSH concentration. Hence, drugs that could prevent the generation of these oxygen free radicals or increase the free radical scavenging enzymes may be effective in alloxan induced diabetes30.

 

In the present study, the observed significant increase in blood glucose level and a decrease in blood glutathione levels in diabetic rats could be due to destruction of ß –cells by alloxan reinforcing the view that alloxan induced diabetes probably through the generation of oxygen free radicals31.

 

 

 

The standard anti-diabetic drug glibenclamide and the test preparations as Drakshasava-T, Drakshasava-M and marketed Drakshasava  showed that they could prevent the development of Diabetes mellitus in albino rats, due to their antioxidant property  since they showed a significant decrease in fasting blood glucose level (FBG) along with significant increase in blood glutathione level (GSH) after treatment.

 

Vehicle control animals were found to be stable in their body weight but diabetic rats showed significant reduction in body weight during 21 days. Alloxan caused body weight reduction, which was improved by standard drug (glibenclamide) and test preparations (Drakshasava-T, Drakshasava-M and marketed Drakshasava) nearly equal to the normal.

 

In general, an increase in blood glucose level is usually accompanied by an increase in plasma cholesterol, triglyceride, LDL levels and a decrease in HDL levels as observed in diabetic patients32. The marked hyperlipidemia that characterizes the diabetic state may be the consequence of the uninhibited actions of lipolytic hormones on fat depots33. Drakshasava-T, Drakshasava-M, marketed Drakshasava and standard antidiabetic glibenclamide produced significant reduction in fasting blood glucose level. These Drakshasava preparations and glibenclamide also produced significant reduction in serum cholesterol, LDL and triglyceride along with significant rise in HDL level in alloxan induced diabetic rats.  Improvement in the lipid profile in diabetic animals after treatment with Drakshasava-T, Drakshasava-M, marketed Drakshasava and standard anti-diabetic glibenclamide could be beneficial in preventing diabetic complications, as well as improving lipid metabolism in diabetic patients34.

 

The decrease in FBG level, improvement in the lipid profile  along with significant rise in the blood glutathione level (GSH) by Drakshasava-T, Drakshasava-M and marketed Drakshasava in alloxan induced diabetic rats suggests that these preparations could be useful  as an antidiabetic agent with cardio-protective activity. The obtained result suggests that the presence of alcohol could be beneficial in the faster absorption of poly-phenolic compounds found present in Drakshasava which are responsible  for showing scavenging of alloxan induced reactive oxygen species. 

 

5. REFERENCES:

1)     Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H , Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Met 2000; 85:2970-2973.

2)     Pickup JC, William G. Epidemiology of Diabetes mellitus. In Textbook of Diabetes. vol.I, 2nd ed. Blackwell, Oxford; 1997. p. 3.1-3.28.

3)     Sagara M, Satoh J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, Muto G, MutoY, Toyota T. Inhibition of  development of peripheral neuropathy in STZ- induced diabetic rats with N-acetylcysteine. Diabetologia 1996; 53:446-449.

4)     Kesari AN, Gupta RK, Watal G. Hypoglycemic effects of Murraya koenigii on normal and alloxan diabetic rabbits. J  Ethnopharmacol 2005; 97: 247-251.

5)     Davidson MB. Diabetes mellitus Diagnosis and treatment. New York: Wiley; 1981. p. 27-48.

6)     The Ayurvedic Formulary of India, Part-II, 2000, 1st edition, The Controller of Publications, Delhi, p.35.

7)     Baydar NG, Ozkan G, Sagdic O. Total phenolic contents and antibacterial activities of grape (Vitis vinifera L.) extracts. Food Control 2004; 15:335-339.

8)     Akoh CC, Bonilla EP, Sellappan S, Krewer G. Phenolic content and antioxidant capacity of Muscadine grapes. Journal of Agricultural and Food Chemistry 2003; 51:5497-5503.

9)     Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. The Lancet 1993; 341(20):454-457.

10)   Mayer AS, Yi OS, Person DA, Waterhouse DL, Frankel EN. Inhibition of human low density lipoprotein oxidation in relation to composition of phenolic antioxidants in grapes (Vitis vinifera). Journal of Agricultural and Food Chemistry 1997; 45:1638-1643.

11)   Teissedre PL, Frankel EN, Waterhouse AL, Peleg H, German GB. Inhibition of in vitro human LDL oxidation by phenolic antioxidants from grapes and wines. Journal of the Science of Food and Agriculture 1996; 70:55-61.

12)   Waterhouse AL. Wine antioxidants may reduce heart disease and cancer. Presentation of American Chemical Society, Washington; 1994.

13)   Renaud S, Lorgeril MD. Wine, alcohol, platelets and the French paradox for coronary heart disease. The Lancet 1992; 339:1523-1526.

14)   Davalos A, Bortolome B, Gomez-cordoves C. Antioxidant properties of commercial grape juices and vinegars. Food Chemistry 2005; 93(2):325-330.

15)   Orhan DD, Orhan N, Ergun E, Ergun F. Hepatoprotective effect of Vitis vinifera L. leaves on carbon tetrachloride-induced acute liver damage in rats. Jornal of Ethnopharmacology 2007; 112:145-151.

16)   Corder R, Mullen W, Khan NQ, Marks SC, Wood EG, Carrier MJ, Crozier A.  Red wine procyanidins and vascular health. Nature 2006;444:566.

17)   Mishra S. Bhaisazya Kalpana Vigyan. Varanasi, India: Chaukambha Surbharati Prakashan; 2005.p. 253-254.

18)   Alam M, Radhamani S, Ali U, Purushottam KK. Microbiological Screening of Dhataki Flowers. Journal of Research in Ayurveda and Siddha 1984; 2(4):371-375.

19)   Nishikant AR, Naresh JG. Antidiabetic Activity of hydro-ethanolic extract of Cyperus rotundus in alloxan induced Diabetes in rats. Fitoterapia 2006; 77:585-588.

20)   Sharma SR, Dwivedi SK, Swarup D. Hypoglycemic and hypolipidemic effects of Cinnamomum tamala Nees leaves. Indian J Exp Biol 1996; 34:372-374.

21)   Giordano BP, Thrash W, Hollenbaugh L, Dube WP, Hodges C, Swain A, Banion CR , Klingensmith GJ. Performance of seven blood glucose testing systems at high altitude. Diabet Educa 1989; 15: 444-448.

22)   Allain CC, Poon LS, Chan CS, Richmond W.   Enzymatic Determination of Total Serum cholesterol. Clin Chem   1974; 20: 471-475.

23)   Muller PH, Schmulling RM, Liebich HM, Eggstein M. A fully Enzymatic Triglyceride Determination. J Clin Chem 1977; 15: 457-464.

24)   Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

25)   Bowers LD. Kinetic Serum Creatinine Assay. The role of various factors in determining specificity. Clin Chem 1980; 26: 551-554.

26)   Wilson BW. Automatic Estimation of urea using urease and alkaline phenol. Clin Chem 1966; 12: 360-368.

27)   Sasaki MA. New method for the determination of serum alkaline phosphatase. Use of Berthelot’s reaction for the estimation of phenol released by enzymatic activity. Igaku To Seibutsugaku 1966; 70: 208-214.

28)   Beutler E, Duron O, Kelly BM. Improved method for determination of blood glutathione. J Lab Med 1963; 61:882-888.

29)   Proks P, Reimann F, Gribble F. Sulfonyl urea stimulation in insulin secretion. Diabetes 2002; 51: S368-76.

30)   Shankar PK, Kumar V, Rao N. Evaluation of Anti-diabetic activity of Ginkgo biloba in streptozotocin induced Diabetic Rats. Iranian J Pharmacol Therapeutics 2005; 4: 16-19.

31)   Wohaleb SA, Godin DV. Alterations in free radical tissue defence mechanism in streptozotocin induced diabetes in rat. Diabetes 1987; 36: 1014-1018.

32)   Mitra SK, Gopumadhvans, Muralidhar TS, Anturlikar SD, Sujatha MB. Effect of D-400, a mineraloherbal preparation on lipid profile, glycosylated haemoglobin and glucose tolerance in streptozotocin induced diabetic rats. Indian J Exp Biol 1995; 33: 798-800.

33)   Bopanna KN, Kanna J, Sushma G, Balaram R, Rathod SP. Antidiabetic and antihyperlipidemic effects of neem seed kernel powder on alloxan diabetic rabbits. Indian J Pharmacol 1997; 29:162-7.

34)   Cho SY, Park JY, Park EM. Alteration of hepatic antioxidant enzyme activities and lipid profile in streptozotocin induced diabetic rats by supplementation of dandelion water extract. Clin Chem Acta 2002; 317: 109-117

 

Received on 17.01.2013

Modified on 01.02.2013

Accepted on 09.02.2013

© A&V Publication all right reserved

Research Journal of Pharmacognosy and Phytochemistry. 5(2): March-April 2013, 87-93